LYMPHOMAS

Mitchell Smith, MD, PhD, discussed the most recent research and agents under investigation for the treatment of indolent lymphomas. He also highlighted how conversations transpire when discussing the watch-and-wait approach with his asymptomatic patients.

Hodgkin Lymphoma

A combination of nivolumab plus brentuximab vedotin was highly active in 73% of patients with relapsed/refractory primary mediastinal large B-cell lymphoma, based on results from the phase I/II CheckMate 436 trial, recently announced during the 15th International Conference on Malignant Lymphoma.<br /> &nbsp;

Lymphoma

Diffuse&nbsp;large B-cell lymphoma is the most common adult non-Hodgkin lymphoma, accounting for about a third of&nbsp;all cases.&nbsp;The World Health Organization classification recognizes over&nbsp;15 subtypes of DLBCL, based on the primary tumor site, specific genetic alterations, or association with specific viruses.

David J. Straus, MD, discusses the toxicities associated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with stage III/IV classical Hodgkin lymphoma, according to data from the 3-year update of the ECHELON-1 trial presented at the 2019 ASCO Annual Meeting.

Polatuzumab vedotin in combination with&nbsp;bendamustine and rituximab has been granted an accelerated approval from the FDA for the&nbsp;treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.<br /> &nbsp;